RDY 56.57 Dr. Reddy's Laboratories Ltd $RDY Hit a 52 week

New Post Public Reply Private Reply Replies (0) Message Board

Nov 13, 2014 at 1:32 PM

RDY 56.57 Dr. Reddy's Laboratories Ltd $RDY Hit a 52 week high of 56.82 Closing the day 09:44 at 56.57 +0.12 +0.21% With a day low of 56.40 and a total volume of 13,958.

RDY Recent Posts: http://investorshangout.com/Dr-Reddys-Laborat...RDY-52499/

RDY Dr. Reddy's Laboratories Ltd Recent Headline News

Dr. Reddy's cleared for generic Valcyte
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 6:34AM CST

ENDP: 67.58 (-0.31), RDY: 56.48 (+0.03)

Dr. Reddy's (RDY) Q2 Earnings Fall, Revenues Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 4:20PM CDT
Dr. Reddy's Laboratories (RDY) reported second-quarter fiscal 2015 earnings per American Depositary Share (ADS) of 54 cents, down 17% from the year-ago quarter.
MNK: 87.13 (-5.86), ACT: 241.51 (+0.89), MYL: 55.42 (+1.62), RDY: 56.48 (+0.03)

Dr. Reddy's Laboratories (RDY) Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Oct 30, 12:50AM CDT

RDY: 56.48 (+0.03)

Dr. Reddys ups revenues 7% in FQ2
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 12:43PM CDT

RDY: 56.48 (+0.03)

Dr. Reddy's FQ2 EPS of $0.54
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 5:55AM CDT

RDY: 56.48 (+0.03)

Dr. Reddy's Q2 and H1 FY15 Financial Results
Business Wire - Wed Oct 29, 5:41AM CDT
--Q2 FY15 EBITDA at Rs. 8.7 billion (24% of the revenues)
RDY: 56.48 (+0.03)

Dr. Reddy's Announces the Launch of Sirolimus Tablets, 1 mg and 2 mg
Business Wire - Tue Oct 28, 12:24PM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Sirolimus Tablets 1 mg and 2 mg, a therapeutic equivalent generic version of RAPAMUNE(R) (Sirolimus) tablets in the US market on October 27, 2014, following the approval by the United States Food & Drug Administration (USFDA).
RDY: 56.48 (+0.03)

Dr. Reddy's reports on October 29
Seeking Alpha - at Seeking Alpha - Fri Oct 17, 6:09AM CDT

RDY: 56.48 (+0.03)

Dr. Reddy's to Release Q2 FY15 Results on October 29, 2014
Business Wire - Fri Oct 17, 4:38AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter ended September 30, 2014 on Wednesday, October 29, 2014 after the Board Meeting. The results will be available on the Company's website www.drreddys.com.
RDY: 56.48 (+0.03)

Sucampo Enters into Settlement Agreement for Amitiza - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 4:50PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) has entered into a settlement agreement with Anchen and Par regarding a patent litigation related to Sucampo's Amitiza.
LCI: 49.21 (-0.52), SCMP: 11.40 (+0.98), RDY: 56.48 (+0.03)

Dr Reddys Laboratories Has Returned 20.3% Since SmarTrend Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 08, 4:57PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 20.35% as of today's recent price of $49.92.
RDY: 56.48 (+0.03)

Dr Reddys Laboratories Shares Up 26.0% Since SmarTrend's Buy Recommendation (RDY)
Comtex SmarTrend(R) - Wed Oct 01, 11:03AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 25.96% as of today's recent price of $52.25.
RDY: 56.48 (+0.03)

Dr. Reddy's (RDY) Generic Xopenex Launched in the US - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:19PM CDT
Dr. Reddy's Laboratories Ltd. (RDY) has launched its generic version of Sunovion Pharmaceuticals Inc.???s Xopenex in the U.S.
SUPN: 8.53 (+0.13), MYL: 55.42 (+1.62), TEVA: 57.71 (-0.73), RDY: 56.48 (+0.03)

Uptrend Call Working As Dr Reddys Laboratories Stock Rises 26.6% (RDY)
Comtex SmarTrend(R) - Wed Sep 24, 9:40AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 26.59% as of today's recent price of $52.51.
RDY: 56.48 (+0.03)

Dr. Reddy's unveils US FDA approved Levalbuterol Inhalation Solution, USP for oral inhalation only
M2 - Wed Sep 24, 7:03AM CDT
Pharmaceutical company Dr. Reddy's Laboratories (NYSE:RDY) reported on Wednesday the market availability of Levalbuterol Inhalation Solution, USP 0.31 mg /3 ml, 0.63 mg /3 ml, 1.25 mg / 3 ml Unit-Dose Vials in the US.
RDY: 56.48 (+0.03)

Dr. Reddy's Announces the Launch of LEVALBUTEROL INHALATION SOLUTION, USP
Business Wire - Wed Sep 24, 2:27AM CDT
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has launched Levalbuterol Inhalation Solution, USP 0.31 mg /3 mL, 0.63 mg /3 mL, 1.25 mg / 3 mL Unit-Dose Vials, a therapeutic equivalent generic version of XOPENEX(R) (levalbuterol hydrochloride) inhalation solution in the US market on September 23, 2014, approved by the United States Food & Drug Administration (USFDA).
RDY: 56.48 (+0.03)

17.9% Return Seen to Date on SmarTrend Dr Reddys Laboratories Call (RDY)
Comtex SmarTrend(R) - Tue Sep 09, 4:52PM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 3 months, Dr Reddys Laboratories has returned 17.91% as of today's recent price of $48.91.
RDY: 56.48 (+0.03)

Uptrend Call Working As Dr Reddys Laboratories Stock Rises 18.5% (RDY)
Comtex SmarTrend(R) - Tue Sep 02, 10:58AM CDT
SmarTrend identified an Uptrend for Dr Reddys Laboratories (NYSE:RDY) on June 26th, 2014 at $41.48. In approximately 2 months, Dr Reddys Laboratories has returned 18.47% as of today's recent price of $49.14.
RDY: 56.48 (+0.03)

Dr. Reddy's Laboratories Ltd. (RDY) Stock Research Links

RDY Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ELEGOO Slashes Prices up to 54% for 2026 Holiday Deals

ELEGOO's 2026 Holiday Strategy: Deep Discounts Welcome to the world of sharp deals and crafty creations as ELEGOO kicks off its Black Friday and Cyber Monday extravaganza. This time, they're slashing prices by up to 54% on their impressive lineup of 3D printers and captivating accessories. Yeah, it's that time of year when wallets might take a hit, but for a good reason....

Ebix and intentyx Tackle AI Security in Regulated Fields

Ebix Aims to Rein in AI Mischief When you throw AI agents into the mix of regulated businesses like insurers, banks, and healthcare outfits, you get a storm brewing. Now, Ebix and intentyx seem to be donning their capes, aiming to bring clarity with their new SMARE security platform. Fancy name notwithstanding, this isn't about mind games—it's about real, observable...

Tennessee Highlights Alarming COPD Rates This November

Tennessee Turns the Spotlight on COPD Here we are again, looking at Tennessee with its weary lung health woes. Governor Bill Lee's newest proclamation for November as COPD Awareness Month is shining a light on a crisis that's been disproportionately hitting the state harder than a sideswipe from a semi. Why the Proclamation Matters Let's cut through the fog—COPD,...

Military Medical Minds to Converge at MTEC Event in 2027

Ever wonder where the cutting edge of military medicine takes shape? On February 16-17, 2027, Washington, DC becomes the epicenter for just that, as the Medical Technology Enterprise Consortium (MTEC) rolls out its 11th Annual Membership Meeting. A gathering of who's who in the world of military medical innovation, this event is like a high-stakes cocktail of science,...

Blokees Joins 'MIKU WITH YOU 2026' Concert in China

Blokees Partners with Iconic Virtual Star Hatsune Miku There's a new player cozying up in the world of virtual icons, and it's none other than Blokees. If you haven't heard, Blokees just dipped its toes into the buzzing waters of the Hatsune Miku fandom by becoming an official strategic partner at the 'MIKU WITH YOU 2026' concert in Shanghai. You could call this a step up...

Julie Boland's Strategic Move to Deere's Board

Deere & Company Expands Leadership with Boland Out of the blue, Deer & Company (NYSE: DE) decided to shake things up by adding Julie Boland, the former U.S. honcho at Ernst & Young LLP, to their board. Now, when Deere gets a leader with her pedigree, there’s more than a whiff of strategy at play. Let’s unpack why Deere's pulling the trigger on this boardroom shift....

Maya Mobile Wins Best Global Roaming Services 2026

Travelers Speak: Maya Tops Global Roaming It's not every day that you see the travel community collectively high-five a company, but that's precisely what happened with Maya Mobile. These folks just snagged the Best Global Roaming Services title at the TripZilla Excellence Awards 2026, and it's not just fluff—it's voted by travelers. This ain't your typical pat on the...

Camect and 3Si Partnership: Revolutionizing Public Safety

Smarter Surveillance with Camect and 3Si A fresh collaboration is stirring the security pot, straight from Silicon Valley's buzzing tech nest. Camect, the brainiacs behind AI-powered video smarts, are shaking hands with 3Si Security Systems. In plain talk, they're hooking up Camect's sharp-eyed video tech with 3Si's DirectToDispatch™ system. This ain’t some techie...

Target Hospitality Readies for Q3 2026 Earnings Reveal

The Thrill of Earnings Season Every trader worth their salt gets a tingle down the spine come earnings season. There's nothing quite like it—the build-up, the anticipation, the potential payouts. This time, we're zeroing in on Target Hospitality, bearing the ticker NASDAQ: TH. Come November 9, 2026, they're set to unveil what the past quarter had up its sleeve, and like...

Ascletis Showcases Bold Moves in Obesity Drug Arena

If you’ve been watching the developments in the world of obesity treatments, Ascletis Pharma is a name you'd do well not to ignore. With ObesityWeek 2026 on the horizon, these folks aren’t just talking—they’re putting their preclinical cards on the table and they’re noteworthy. Unveiling Future Contenders Ascletis is gearing up to present some of their...